Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received~* HER-2 overexpression 2+ or 3+ using IHC or FISH +~* Measurable disease~* At least one prior chemotherapy regimen~* Not in a prior irradiation field~* No patients with brain metastatic disease who has not been irradiated or uncontrolled brain metastatic disease after irradiation~* No more than 25% of myeloproductive bone marrow irradiated. More than 4 weeks since prior radiotherapy and recovered~* Age 18 - 75 year old~* Performance status (WHO) 0-2~* Life expectancy more than 12 weeks~* Absolute neutrophil count \> 1500/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (bilirubin \< 2 mg/dL, SGOT/SGPT \< 2 times upper limit of normal, ALP \< 3 times upper limit of normal, creatinine \< 1.5 upper limit of normal~* Adequate cardiac function (LVEF \> 50%)~Exclusion Criteria:~* Pregnant or nursing~* Positive pregnancy test~* Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce P-450 cytochrome~* Motor or sensory neuropathy \> grade 1 according to NCIC toxicity criteria~* History of allergic reaction attributed to docetaxel~* Psychiatric illness or social situation that would preclude study compliance~* Other concurrent uncontrolled illness~* Other invasive malignancy within the past 5 years except cured basal cell skin carcinoma and cervical carcinoma in situ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): GHer
- 2 (Type: EXPERIMENTAL): CapHer

Based on this trial design, predict the completion outcome and termination type (if applicable).